Endogenous Cushing’s Syndrome – FDA Approves Korlym (Mifepristone) – Medical News Today
Endogenous Cushing's Syndrome - FDA Approves Korlym (Mifepristone) Medical News Today Until the FDA approved Korlym for the treatment of endogenous Cushing's syndrome, there were no approved medications to treat the disorder. Endogenous Cushing's syndrome is a debilitating and rare multisystem disorder which affects individuals mainly ... Corcept Therapeutics (CORT) Surged To Nearly An 8-Month High After FDA Approval FDA approves Corcept Korlym oral medicine Korlym Approved for Cushing's Syndrome |
Leave a Comment
Recommended Sites
0 Comments
You can be the first one to leave a comment.